FindTrial
Sign In

Digital Rectal Examination

PROCEDURE6 trials

Sponsors

Case Comprehensive Cancer Center, National Cancer Institute (NCI), Mayo Clinic, City of Hope Medical Center, Emory University

Conditions

AIDS-Related Anal CarcinomaAnal Basaloid CarcinomaAnal Canal Cloacogenic CarcinomaAnal Margin Squamous Cell CarcinomaAnal Non-Keratinizing Squamous Cell CarcinomaAnal Squamous Cell CarcinomaColon CarcinomaColorectal Carcinoma

Phase 2

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
Active, not recruitingNCT04929028
National Cancer Institute (NCI)AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma +7
Start: 2022-08-09End: 2031-09-15Target: 40Updated: 2026-04-03
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
RecruitingNCT06780787
City of Hope Medical CenterRectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Start: 2025-05-20End: 2027-11-05Target: 26Updated: 2025-06-26
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
Not yet recruitingNCT07405476
Emory UniversityColon Carcinoma, Colorectal Carcinoma, Rectal Carcinoma +9
Start: 2026-03-01End: 2029-12-18Target: 38Updated: 2026-02-12

Phase 3

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Active, not recruitingNCT03233711
National Cancer Institute (NCI)Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma +2
Start: 2018-07-05End: 2027-12-31Target: 344Updated: 2026-04-03

Unknown Phase

Informed Decision Making Intervention in Screening for Prostate Cancer of Predominantly African American Participants in a Community Outreach Program
TerminatedNCT02419846
Case Comprehensive Cancer CenterProstate Carcinoma
Start: 2015-06-01End: 2022-07-31Updated: 2022-07-25
MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer
RecruitingNCT05438563
Mayo ClinicProstate Carcinoma, Stage II Prostate Cancer AJCC v8, Stage I Prostate Cancer AJCC v8
Start: 2022-04-06End: 2027-03-07Target: 100Updated: 2025-09-09

Related Papers

Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders
Journal for ImmunoTherapy of Cancer2024-01-0110 citations
Informed decision making (IDM) for prostate cancer (PCa) screening in a high-risk population.
Journal of Clinical Oncology2017-02-203 citations